➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Medtronic
Harvard Business School
McKinsey
McKesson

Last Updated: September 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,246,980


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,246,980 protect, and when does it expire?

Patent 8,246,980 protects NEUPRO and is included in one NDA.

This patent has twenty-six patent family members in twenty-one countries.

Summary for Patent: 8,246,980
Title:Transdermal delivery system
Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains an amine-functional drug in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of the amine-functional drug and is impermeable to the protonated form of the amine-functional drug.
Inventor(s): Schacht; Dietrich Wilhelm (Koln, DE), Hannay; Mike (Wachtberg-Villiprott, DE), Wolff; Hans-Michael (Monheim, DE)
Assignee: UCB Pharma GmbH (Monheim, DE)
Application Number:10/627,990
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,246,980
Patent Claim Types:
see list of patent claims
Delivery; Compound;

Drugs Protected by US Patent 8,246,980

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-001 May 9, 2007 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,246,980

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02016864Jul 30, 2002

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Johnson and Johnson
Baxter
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.